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ABSTRACT
Lay, C.-S., Tsai, Y.-T., Teg, C.-Y., Shyu, W.-S., Guo, W.-
S., Wu, K.-L. and Lo, K.-J. (1997) Endoscopic variceal
ligation in prophylaxis of first variceal bleeding in
ciorrhotic patients with high-risk esophageal varices.
Hepatology; 25, 1346-1350.
prophylactic EVL can decrease the incidence of first
variceal bleeding and death over a period of 2 years
in cirrhotic patients with high-risk esophageal
varices. (Hepatology, 1997; 25, 1346-1350).
To determine the efficacy of endoscopic variceal
ligation (EVL) in prophylaxis on the rate of first
esophageal variceal bleeding, we conducted a pro-
spective, randomized trial in 126 cirrhotic patients
with no history of previous upper gastrointestinal
bleeding and with esophageal varices endoscopically
judged to be at high risk of hemorrhage. The end-
points of the study were bleeding and death. Life-
table curves showed that prophylactic EVL signifi-
cantly diminished the rate of variceal hemorrhage
(12/62 [19%] vs. 38/64 [60%]; P 0.0001) and overall
mortality (17/62 [28% vs. 37/64 [58% ];P 0.0021). The
2 year cumulative bleeding rate was 19% (12/62) in
the EVL group and 60% (38/64) in the control group.
The 2 year cumulative mortality rate was 28% (17/62)
in the EVL group and 58% (37/64) in the control
group. Comparison of Kaplan-Meier estimates of the
time to death of both groups showed significantly
lower mortality in the ligation group (P=0.001).
Patients undergoing EVL had few treatment failures
and died mainly of hepatic failure. The lower risk in
the EVL group was attributed to a rapid reduction of
variceal size. Prophylactic EVL was more efficient in
preventing first bleeding in patients with good
condition (Child A) than in those with decompen-
sated disease (Child B and C). We conclude that
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PAPER DISCUSSION
Endoscopic treatment as prophylaxis against a
first variceal bleed (primary prophylaxis) is not
widely accepted outside of Japan. The most
studied prophylactic endoscopic treatment is
sclerotherapy. Western patients judged to be at
high risk for a first variceal bleed and treated
with endoscopic sclerotherapy fared better than
those who had no treatment in some trials [1]
and had outcomes equal or worse than those
who received no treatment in the others [2].
Western physicians, with few exceptions, have
moved away from further consideration of
endoscopic sclerotherapy as a viable method
for prevention of a first variceal bleed and have
focused instead on drug therapy.
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Lay et al., from Taiwan, report results from the
second trial of endoscopic band ligation as
primary prophylaxis [3]. Patients with cirrhosis
and portal hypertension from hepatitis B were
evaluated using criteria developed by the
Japanese Research Society for Portal Hyperten-
sion and Beppu to assess risk of hemorrhage
[4, 5]. Those at high risk for a first variceal bleed
by these criteria were randomized to endoscopic
band ligation or no treatment. Endoscopic
ligation was performed using the original single
fire ligating device delivered via an endoscopic
overtube. As in the first trial, performed by Sarin
et al., in India, patients treated with endoscopic
ligation had. significantly less chance of experi-
encing a first variceal bleed, few complications
related to endoscopic treatment, and less chance
of dying (statistically less in the current study; a
trend in Sarin’s trial) [6].
Is it time for those in the West to rethink the
role of the endoscopist in prophylaxis against a
first variceal bleed? There is little question that
endoscopic band ligation is associated with
fewer complications than sclerotherapy. Band
ligation also results in faster eradication of
varices (fewer treatments to eradicate) although
it is hard to understand how this advantage
could prevent bleeding in patients who have not
yet bled. On the other hand, in most trials which
compared ligation with sclerotherapy for pre-
vention of recurrent variceal hemorrhage, liga-
tion was associated with less chance for further
bleeding than sclerotherapy [7]. Perhaps the
occasional deep sclerosant induced ulcer, or
what appears to be greater local inflammatory
response elicited by sclerosant injection, is
responsible for a higher risk of hemorrhage with
sclerotherapy treatment. It is true that patients
treated with band ligation have a greater
incidence of recurrence of varices, once initial
eradication of varices has been achieved, than
those treated with sclerotherapy; however, with
proper surveillance and repeat treatment if
needed, the practical consequences are few.
The biggest single advantage for band ligation
over sclerotherapy, in my opinion, is its relative
lack of operator dependence. Once the endo-
scopic ligator is delivered to the target area, the
operator does little but select the target, push
the endoscope suction button, and pull a string.
The resulting tissue effects are homogeneous,
reproducible, and are confined to the mucosa
and submucosa [8]. The only operator critical
component of traditional band ligation is over-
tube placement. In most large trials of secondary
prophylaxis, as in the two trials of primary
prophylaxis, overtube related problems are
uncommon. Scattered reports of overtube in-
duced mucosai injury or perforation have
focused attention on this potential disadvantage
of band ligation. Introduction of multiple-fire
ligating devices has eliminated the need for an
overtube, albeit at significantly increased cost.
Safety and reproducibility of results are key
requirements for successful treatment aimed at
prevention of a first variceal bleed. Only about
one in three patients with cirrhosis and varices
ever bleed [9]. Unnecessary treatment of two
thirds, particularly with an invasive treatment
such as endoscopy, is difficult to advocate. Only
if identification of those patients at high risk for
a first bleed can be consistently achieved (60%
incidence of hemorrhage in the Lay study
control group) can endoscopic measured be
justified.
Pharmacological treatment with beta adrener-
gic receptor blocking agents has been shown
effective in decreasing the risk of a first variceal
bleed and probably reduces mortality when
compared with no treatment [10]. Drug therapy
is based on sound physiologic principles, is
relatively inexpensive, has the intrinsic appeal of
being completely operator independent,
(although it is very patient dependent) and is
administrable by anyone who is authorized to
write a prescription. Addition of isosorbide
mononitrate to the prophylactic beta-blockade
regimen has been shown, in one trial, to result in
even greater protection [11]. This study and
results from trials examining the two drugHPB INTERNATIONAL 197
regimen for secondary prophylaxis argue for a
two drug regimen in future pharmacological
trials of primary prophylaxis.
The two published trials which demonstrate
efficacy of band ligation for primary prophylaxis
do not yet justify a conclusion that this treatment
should be recommended for patients with
cirrhosis and varices which have not bled-even
for those at high risk of a first bleed. It is safe to
conclude that band ligation has the potential to
become established as a safe and effective
method for prevention of a first variceal bleed,
but further confirmation is needed. Future trials
of endoscopic prophylaxis should avoid an
untreated control arm and compare band liga-
tion with a one or two drug regimen in patients
who are determined to be at high risk for a first
bleed.
I predict that drug therapy and endoscopic
band ligation will eventually be found equally
effective for prevention of a first variceal bleed.
Patients themselves will determine which regi-
men is superior. Those who have capacity for
compliance with a daily, lifelong, drug regimen
will probably be best treated with medications.
Others who are less compliant, are’intolerant of
the medications, or who desire a finite period of
treatment, will be best served with the endo-
scopic solution.
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